LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

Search

Simulations Plus Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

19.19 1.43

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

19.05

Max

19.5

Pagrindiniai rodikliai

By Trading Economics

Pajamos

67M

-681K

Pardavimai

-2.9M

17M

P/E

Sektoriaus vid.

48.528

78.892

Pelnas, tenkantis vienai akcijai

-0.034

Dividendų pajamingumas

0.48

Pelno marža

-3.9

Darbuotojai

212

EBITDA

327K

5.3M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+6.05% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.48%

2.38%

Kitas uždarbis

2026-01-08

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

45M

390M

Ankstesnė atidarymo kaina

17.76

Ankstesnė uždarymo kaina

19.19

Naujienos nuotaikos

By Acuity

50%

50%

164 / 374 reitingas Healthcare

Simulations Plus Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-24 21:41; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

2025-12-24 14:57; UTC

Įsigijimai, susijungimai, perėmimai

Accenture to Acquire Cabel Industry from Fibonacci Group

2025-12-24 12:48; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

Repare Therapeutics Shares Rise on $30 Million Asset Deal With Gilead

2025-12-24 12:21; UTC

Pagrindinės rinkos jėgos

Nike Shares Tick Up After Apple CEO Tim Cook Buys $2.9 Million of Its Stock

2025-12-24 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

2025-12-24 21:26; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

2025-12-24 19:35; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-24 19:35; UTC

Rinkos pokalbiai

Treasury Yields Decline Ahead of Christmas -- Market Talk

2025-12-24 19:09; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

2025-12-24 19:09; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

2025-12-24 19:06; UTC

Rinkos pokalbiai

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

2025-12-24 19:03; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Give Back Some Gains -- Market Talk

2025-12-24 17:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-12-24 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-24 17:08; UTC

Įsigijimai, susijungimai, perėmimai

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

2025-12-24 16:53; UTC

Įsigijimai, susijungimai, perėmimai

Nike Climb Boosts Dow, S&P 500 -- WSJ

2025-12-24 16:31; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

ServiceNow Gets Top-Tier Asset and Talent With Armis Buy -- Market Talk

2025-12-24 16:28; UTC

Įsigijimai, susijungimai, perėmimai

Lam Research Is at All-Time Highs. Its CEO Just Sold $27 Million Worth of Stock. -- Barrons.com

2025-12-24 16:17; UTC

Rinkos pokalbiai

Dollar Stable as U.S. Layoffs Remain at Bay -- Market Talk

2025-12-24 15:33; UTC

Įsigijimai, susijungimai, perėmimai

Nike Shares Get a Lift After Apple's Tim Cook Doubles His Personal Stake -- WSJ

2025-12-24 15:30; UTC

Įsigijimai, susijungimai, perėmimai

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

2025-12-24 15:19; UTC

Įsigijimai, susijungimai, perėmimai

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

2025-12-24 14:49; UTC

Įsigijimai, susijungimai, perėmimai

Mexico's Ollamani Sells Stake in Azteca Stadium

2025-12-24 14:19; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Move Lower After Big Jump -- Market Talk

2025-12-24 14:08; UTC

Įsigijimai, susijungimai, perėmimai

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

2025-12-24 14:06; UTC

Rinkos pokalbiai

Oil Futures Edge Up on Geopolitical Risk Premium -- Market Talk

2025-12-24 13:24; UTC

Rinkos pokalbiai

Canada's Economy Needs More Help Amid Dismal GDP Report -- Market Talk

2025-12-24 12:59; UTC

Įsigijimai, susijungimai, perėmimai

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

2025-12-24 12:51; UTC

Įsigijimai, susijungimai, perėmimai

Disney Could Be the Real Winner from the Warner Takeover Battle. Here's Why. -- Barrons.com

2025-12-24 12:38; UTC

Įsigijimai, susijungimai, perėmimai

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Simulations Plus Inc Prognozė

Kainos tikslas

By TipRanks

6.05% į viršų

12 mėnesių prognozė

Vidutinis 20.5 USD  6.05%

Aukščiausias 25 USD

Žemiausias 16 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Simulations Plus Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

5 ratings

2

Pirkti

3

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

164 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat